Regulatory T lymphocytes expressing L-selectin in children and adolescents with type 1 diabetes mellitus;Limfocyty T regulatorowe z ekspresja̧ L-selektyny u dzieci i młodzieży z przewlekła̧ cukrzyca̧ typu 1

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 16, Issue 1, 2010, Pages 12-16

  Ryba, Monika ^a   Hak, Łukasz ^a   Zorena, Katarzyna ^a   Myśliwiec, Małgorzata ^b   Myśliwska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Klinika Pediatrii   (Poland)

Author keywords

CD62L; Children and adolescents; Diabetes type 1; Foxp3; Regulatory T cells

Indexed keywords

CD3 ANTIBODY; HEMOGLOBIN A1C; L SELECTIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; REGULATORY T LYMPHOCYTE;

EID: 84904843163     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bach J.F., Chatenoud L.: Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol., 2001, 19, 131-161.
2. Hori S., Takahashi T., Sakaguchi S.: Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv. Immunol., 2003, 81, 331-371.
3. Hori S., Nomura T., Sakaguchi S.: Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299, 1057-1061.
4. + regulatory T cells. Nat. Immunol., 2003, 4, 330-336.
5. Brusko T.M., Putnam A.L., Bluestone J.A.: Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev., 2008, 223, 371-390.
6. Kukreja A., Cost G., Marker J. i wsp.: Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest., 2002, 109, 131-140.
7. + T-cells from patients with type 1 diabetes. Diabetes, 2005, 54, 92-99.
8. Ehrenstein M.R., Evan J.G., Singh A. i wsp.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med., 2004, 200, 277-285.
9. Łuczyński W., Stasiak-Barmuta A., Urban R. i wsp.: Lower percentages of T regulatory cells in children with type 1 diabetes - preliminary report. Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw., 2009, 15, 34-38.
10. + T Cells That Prevent Diabetes Onset in Nonobese Diabetic Mice. J. Immunol., 2000, 164, 240-247.
11. +splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol., 2002, 169, 2461-2465.
12. Arbones M.L., Ord D.C., Ley K. i wsp.: Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity, 1994, 1, 247-260.
13. + regulatory T cells protects from lethal acute GVHD. Blood, 2005, 105, 2220-2226.
14. + T regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood, 2004, 104, 3804-3812.
15. + regulatory T cells in the hematolymphoid system. Exp. Hematol., 2006, 34, 1033-1040.
16. Myśliwiec M., Zorena K., Balcerska A., Myśliwska J.: Does tumor necrosis factor-α preceed occurence of microalbuminuria in type 1 diabetes mellitus children? Exp. Clin. Diabetol., 2006, 6, 131-136.
17. Zorena K., Myśliwiec M., Balcerska A. i wsp.: Tumor necrosis factor-α is a risk factor of retinopathy in poor controlled type 1 diabetes mellitus of children. Exp. Clin. Diabetol., 2006, 6, 169-173.
18. Gustavsson C., Agardh E., Bengtsson B., Agardh C.D.: TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J. Diabetes Complications, 2008, 22, 309-316.
19. + regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov. Today, 2007, 12, 548-552.
20. + regulatory T cells in children afected by Crohn's disease. Immunology, 2008, 125, 178-183.
21. hi T regulatory cells. Blood, 2006, 108, 253-261.
22. American Diabetes Association: Diagnosis and Classifcation of Diabetes. Diabetes Care, 2003, 26, 3160-3167.
23. + regulatory T lymphocytes expressing CD62L in patients with long-standing diabetes type 1. Centr. Eur. J. Immunol. 2009, 34, 90-93.
24. + T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes, 2007, 56, 1395-1402.
25. + T-cells in type 1 diabetes. Diabetes, 2005, 54, 1407-1414.
26. + regulatory T-cells in type 1 diabetes. Diabetes, 2007, 56, 604-612.
27. + T regulatory cells. J. Immunol. 2007, 179, 154-161.
28. Sheetz M.J., King G.L.: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 2002, 288, 2579-2588.
29. Vogl-Willis C.A., Edwards I.J.: High glucose induced alterations in subendothelial matrix perlecan leads to increases monocyte binding. Artherioscler Thromb. Vasc. Biol., 2004, 24, 858-863.